Financials

News Ideas Technicals Forecast

SMMT fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

SMMT does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company